BIOGEN INC (1BIIB.MI) Stock Fundamental Analysis

BIT:1BIIB • US09062X1037

144.45 EUR
-6.45 (-4.27%)
Last: Jan 15, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to 1BIIB. 1BIIB was compared to 77 industry peers in the Biotechnology industry. 1BIIB has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. 1BIIB is valued quite cheap, but it does not seem to be growing. These ratings would make 1BIIB suitable for value investing!


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • 1BIIB had positive earnings in the past year.
  • In the past year 1BIIB had a positive cash flow from operations.
  • 1BIIB had positive earnings in each of the past 5 years.
  • In the past 5 years 1BIIB always reported a positive cash flow from operatings.
1BIIB.MI Yearly Net Income VS EBIT VS OCF VS FCF1BIIB.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

1.2 Ratios

  • The Return On Assets of 1BIIB (5.51%) is better than 82.95% of its industry peers.
  • Looking at the Return On Equity, with a value of 8.84%, 1BIIB belongs to the top of the industry, outperforming 81.82% of the companies in the same industry.
  • 1BIIB has a Return On Invested Capital of 9.70%. This is amongst the best in the industry. 1BIIB outperforms 87.50% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for 1BIIB is in line with the industry average of 11.65%.
Industry RankSector Rank
ROA 5.51%
ROE 8.84%
ROIC 9.7%
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
1BIIB.MI Yearly ROA, ROE, ROIC1BIIB.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

1.3 Margins

  • 1BIIB has a Profit Margin of 15.98%. This is amongst the best in the industry. 1BIIB outperforms 82.95% of its industry peers.
  • 1BIIB's Profit Margin has declined in the last couple of years.
  • The Operating Margin of 1BIIB (28.50%) is better than 86.36% of its industry peers.
  • In the last couple of years the Operating Margin of 1BIIB has declined.
  • Looking at the Gross Margin, with a value of 75.24%, 1BIIB is in the better half of the industry, outperforming 67.05% of the companies in the same industry.
  • 1BIIB's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 28.5%
PM (TTM) 15.98%
GM 75.24%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
1BIIB.MI Yearly Profit, Operating, Gross Margins1BIIB.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • 1BIIB has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • Compared to 1 year ago, 1BIIB has more shares outstanding
  • 1BIIB has less shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, 1BIIB has an improved debt to assets ratio.
1BIIB.MI Yearly Shares Outstanding1BIIB.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
1BIIB.MI Yearly Total Debt VS Total Assets1BIIB.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

2.2 Solvency

  • 1BIIB has an Altman-Z score of 3.25. This indicates that 1BIIB is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of 1BIIB (3.25) is better than 70.45% of its industry peers.
  • The Debt to FCF ratio of 1BIIB is 2.78, which is a good value as it means it would take 1BIIB, 2.78 years of fcf income to pay off all of its debts.
  • 1BIIB's Debt to FCF ratio of 2.78 is amongst the best of the industry. 1BIIB outperforms 84.09% of its industry peers.
  • A Debt/Equity ratio of 0.35 indicates that 1BIIB is not too dependend on debt financing.
  • 1BIIB has a Debt to Equity ratio of 0.35. This is comparable to the rest of the industry: 1BIIB outperforms 59.09% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF 2.78
Altman-Z 3.25
ROIC/WACC1.16
WACC8.36%
1BIIB.MI Yearly LT Debt VS Equity VS FCF1BIIB.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.3 Liquidity

  • 1BIIB has a Current Ratio of 2.72. This indicates that 1BIIB is financially healthy and has no problem in meeting its short term obligations.
  • 1BIIB has a Current ratio of 2.72. This is comparable to the rest of the industry: 1BIIB outperforms 57.95% of its industry peers.
  • A Quick Ratio of 2.04 indicates that 1BIIB has no problem at all paying its short term obligations.
  • 1BIIB has a Quick ratio (2.04) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 2.72
Quick Ratio 2.04
1BIIB.MI Yearly Current Assets VS Current Liabilites1BIIB.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • 1BIIB shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.51%.
  • 1BIIB shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -13.31% yearly.
  • Looking at the last year, 1BIIB shows a small growth in Revenue. The Revenue has grown by 4.77% in the last year.
  • Measured over the past years, 1BIIB shows a decrease in Revenue. The Revenue has been decreasing by -7.62% on average per year.
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%

3.2 Future

  • Based on estimates for the next years, 1BIIB will show a small growth in Earnings Per Share. The EPS will grow by 0.59% on average per year.
  • 1BIIB is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.63% yearly.
EPS Next Y-7.36%
EPS Next 2Y-3.15%
EPS Next 3Y-0.51%
EPS Next 5Y0.59%
Revenue Next Year1.98%
Revenue Next 2Y-1.62%
Revenue Next 3Y-1.2%
Revenue Next 5Y-0.63%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
1BIIB.MI Yearly Revenue VS Estimates1BIIB.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B
1BIIB.MI Yearly EPS VS Estimates1BIIB.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

7

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 10.13, the valuation of 1BIIB can be described as very reasonable.
  • Based on the Price/Earnings ratio, 1BIIB is valued cheaper than 96.59% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 27.10. 1BIIB is valued rather cheaply when compared to this.
  • The Price/Forward Earnings ratio is 10.98, which indicates a very decent valuation of 1BIIB.
  • 97.73% of the companies in the same industry are more expensive than 1BIIB, based on the Price/Forward Earnings ratio.
  • When comparing the Price/Forward Earnings ratio of 1BIIB to the average of the S&P500 Index (28.06), we can say 1BIIB is valued rather cheaply.
Industry RankSector Rank
PE 10.13
Fwd PE 10.98
1BIIB.MI Price Earnings VS Forward Price Earnings1BIIB.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • 1BIIB's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. 1BIIB is cheaper than 94.32% of the companies in the same industry.
  • 1BIIB's Price/Free Cash Flow ratio is rather cheap when compared to the industry. 1BIIB is cheaper than 96.59% of the companies in the same industry.
Industry RankSector Rank
P/FCF 11
EV/EBITDA 7.46
1BIIB.MI Per share data1BIIB.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60 80 100

4.3 Compensation for Growth

  • 1BIIB has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.15%
EPS Next 3Y-0.51%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for 1BIIB!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BIOGEN INC

BIT:1BIIB (1/15/2026, 7:00:00 PM)

144.45

-6.45 (-4.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-30
Earnings (Next)02-06
Inst Owners96.04%
Inst Owner ChangeN/A
Ins Owners0.15%
Ins Owner ChangeN/A
Market Cap21.19B
Revenue(TTM)10.07B
Net Income(TTM)1.61B
Analysts73.33
Price Target163.34 (13.08%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.2%
Min EPS beat(2)21.48%
Max EPS beat(2)38.92%
EPS beat(4)4
Avg EPS beat(4)19.59%
Min EPS beat(4)0.67%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)14.8%
EPS beat(12)12
Avg EPS beat(12)12.19%
EPS beat(16)14
Avg EPS beat(16)11.4%
Revenue beat(2)2
Avg Revenue beat(2)8.93%
Min Revenue beat(2)6.23%
Max Revenue beat(2)11.62%
Revenue beat(4)4
Avg Revenue beat(4)6.16%
Min Revenue beat(4)0.11%
Max Revenue beat(4)11.62%
Revenue beat(8)5
Avg Revenue beat(8)2.19%
Revenue beat(12)9
Avg Revenue beat(12)2.33%
Revenue beat(16)11
Avg Revenue beat(16)2%
PT rev (1m)6.01%
PT rev (3m)10.35%
EPS NQ rev (1m)1.04%
EPS NQ rev (3m)-53.64%
EPS NY rev (1m)-1.67%
EPS NY rev (3m)-5.23%
Revenue NQ rev (1m)0.09%
Revenue NQ rev (3m)-2.21%
Revenue NY rev (1m)0.62%
Revenue NY rev (3m)1.55%
Valuation
Industry RankSector Rank
PE 10.13
Fwd PE 10.98
P/S 2.47
P/FCF 11
P/OCF 10.14
P/B 1.37
P/tB 10.43
EV/EBITDA 7.46
EPS(TTM)14.26
EY9.87%
EPS(NY)13.16
Fwd EY9.11%
FCF(TTM)13.13
FCFY9.09%
OCF(TTM)14.24
OCFY9.86%
SpS58.44
BVpS105.7
TBVpS13.85
PEG (NY)N/A
PEG (5Y)N/A
Graham Number184.16
Profitability
Industry RankSector Rank
ROA 5.51%
ROE 8.84%
ROCE 11.07%
ROIC 9.7%
ROICexc 11.44%
ROICexgc 40.96%
OM 28.5%
PM (TTM) 15.98%
GM 75.24%
FCFM 22.48%
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexgc growth 3Y14.15%
ROICexgc growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score5
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF 2.78
Debt/EBITDA 1.73
Cap/Depr 25.04%
Cap/Sales 1.9%
Interest Coverage 250
Cash Conversion 67.56%
Profit Quality 140.63%
Current Ratio 2.72
Quick Ratio 2.04
Altman-Z 3.25
F-Score5
WACC8.36%
ROIC/WACC1.16
Cap/Depr(3y)54.43%
Cap/Depr(5y)68.89%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.34%
Profit Quality(5y)120.98%
High Growth Momentum
Growth
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
EPS Next Y-7.36%
EPS Next 2Y-3.15%
EPS Next 3Y-0.51%
EPS Next 5Y0.59%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
Revenue Next Year1.98%
Revenue Next 2Y-1.62%
Revenue Next 3Y-1.2%
Revenue Next 5Y-0.63%
EBIT growth 1Y15.15%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year3.51%
EBIT Next 3Y0.64%
EBIT Next 5Y1.51%
FCF growth 1Y120.5%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y80.46%
OCF growth 3Y-7.56%
OCF growth 5Y-16.49%

BIOGEN INC / 1BIIB.MI FAQ

What is the ChartMill fundamental rating of BIOGEN INC (1BIIB.MI) stock?

ChartMill assigns a fundamental rating of 6 / 10 to 1BIIB.MI.


What is the valuation status of BIOGEN INC (1BIIB.MI) stock?

ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (1BIIB.MI). This can be considered as Undervalued.


Can you provide the profitability details for BIOGEN INC?

BIOGEN INC (1BIIB.MI) has a profitability rating of 7 / 10.


What are the PE and PB ratios of BIOGEN INC (1BIIB.MI) stock?

The Price/Earnings (PE) ratio for BIOGEN INC (1BIIB.MI) is 10.13 and the Price/Book (PB) ratio is 1.37.


What is the expected EPS growth for BIOGEN INC (1BIIB.MI) stock?

The Earnings per Share (EPS) of BIOGEN INC (1BIIB.MI) is expected to decline by -7.36% in the next year.